CDK4 and neoplasm: Second-generation selective CDK4/6 inhibitors, including palbociclib, ribociclib, and abemaciclib, can induce G1 phase cell cycle arrest in RB-positive tumor models with improved effectiveness and reduced adverse effects [9–17].